Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price target among brokers that have covered the stock in the last year is $9.57.

A number of research firms have weighed in on PYXS. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Thursday, September 19th. Stephens assumed coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Friday, August 16th. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They issued a “buy” rating and a $10.00 price target on the stock.

Pyxis Oncology Price Performance

PYXS stock opened at $4.19 on Monday. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85. The company has a market cap of $249.18 million, a P/E ratio of -4.07 and a beta of 1.27. The stock’s fifty day moving average price is $3.69 and its 200-day moving average price is $3.65.

Hedge Funds Weigh In On Pyxis Oncology

A number of hedge funds have recently modified their holdings of PYXS. StemPoint Capital LP purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $7,643,000. Ikarian Capital LLC bought a new stake in Pyxis Oncology during the first quarter valued at about $7,082,000. Blue Owl Capital Holdings LP purchased a new position in shares of Pyxis Oncology in the second quarter valued at about $3,462,000. Millennium Management LLC boosted its stake in shares of Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Pyxis Oncology during the third quarter worth about $1,405,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.